Survival Analysis of Biliary Tract Cancer Cases in Turkey

  • Akca, Zeki ;
  • Mutlu, Hasan ;
  • Erden, Abdulsamet ;
  • Buyukcelik, Abdullah ;
  • Cihan, Yasemin Benderli ;
  • Goksu, Sema Sezgin ;
  • Aslan, Tuncay ;
  • Sezer, Emel Yaman ;
  • Inal, Ali
  • Published : 2014.08.15


Background: Because of the relative rarity of biliary tract cancers (BTCs), defining long term survival results is difficult. In the present study, we aimed to evaluate the survival of a series of cases in Turkey. Materials and Methods: A totally of 47 patients with billiary tract cancer from Mersin Goverment Hospital, Acibadem Kayseri Hospital and Kayseri Training and Research Hospital were analyzed retrospectively using hospital records between 2006-2012. Results: The median overall survival was $19.3{\pm}3.9$ months for all patients. The median disease free and overall survivals were $24.3{\pm}5.3$ and $44.1{\pm}12.9$ months in patients in which radical surgery was performed, but in those with with inoperable disease they were only $5.3{\pm}1.5$ and $10.7{\pm}3.2$ months, respectively. Conclusions: BTCs have a poor prognosis. Surgery with a microscopic negative margin is still the only curative treatment.


Biliary tract cancer;cholangiocarcinoma;survival;gallbladder;Ampulla vateri


  1. Ahmad Z, Arshad H, Fatima S et al (2013). Gastrointestinal, liver and biliary tract pathology: a histopathological and epidemiological perspective from Pakistan with a review of the literature. Asian Pac J Cancer Prev, 14, 6997-7005.
  2. Aljiffry M, Walsh MJ, Molinari M (2009). Advances in diagnosis, treatment and palliation of cholangiocarcinoma, World J Gastroenterol, 15, 4240-62. Review
  3. AndreT, Tournigand C, Rosmorduc O et al (2004). Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 15, 1339-43
  4. Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM (2003). Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer, preliminary report. Oncology (Williston Park), 17, 23-6
  5. Butte JM, Matsuo K, Gonen M et al (2011). Gallbladder cancer, Differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg, 212, 50-61
  6. Chang KY, Chang JY, Yen Y (2009). Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw, 7, 423-7.
  7. Cleary SP, Knoxx J, Dawson LA (2011). Carcinoma of the biliary tract. In, Blanke CD, Rodel C, Talamonti MS, editors. Gastrointestinal Oncol. Berlin, Springer, P. 251.
  8. DeOliveira ML, Cunningham SC, Cameron JL et al (2007). Cholangiocarcinoma, thirty-one-year experience with 564 patients at a single institution. Ann Surg, 245, 755-62.
  9. Greene FL, Page DL, Fleming ID (2002). AJCC cancer staging manual, 6th edn. Springer, New York.
  10. Knox JJ, Hedley D, Oza A et al ( 2005). Combining gemcitabine and capecitabine in patients with advanced biliary cancer, a phase II trial. J Clin Oncol, 23, 2332-8
  11. Lee BS, Hwang JH, Lee SH et al (2012). Older adults with biliary tract cancer, treatment and prognosis. J Am Geriatr Soc, 60, 1862-71
  12. Shaib YH, Davila JA, Henderson L, McGlynn KA, El-Serag HB (2007). Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the United States, A population-based study. J Clin Gastroenterol, 41, 911-7
  13. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K (2012). Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg, 99, 1711-7.
  14. Pattanathien P, Khuntikeo N, Promthet S, Kamsa-Ard S (2013). Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac J Cancer Prev, 14, 321-4
  15. Sun TT, Wang JL, Fang JY (2013). Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas, an overview of clinical evidence. Asian Pac J Cancer Prev, 14, 877-83.
  16. Unal OU, Oztop I, Unek IT, Yilmaz AU (2013).Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. Asian Pac J Cancer Prev, 14, 5263-7
  17. Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81
  18. Vauthey JN, Blumgart LH (1994). Recent advances in the management of cholangiocarcinomas. Semin Liver Dis, 14, 109-14.
  19. Woradet S, Promthet S, Songserm N, Parkin DM (2013). Factors affecting survival time of cholangiocarcinoma patients, a prospective study in Northeast Thailand. Asian Pac J Cancer Prev, 14, 1623-7.
  20. Zhu AX, Hong TS, Hezel AF, Kooby DA (2010). Current management of gallbladder carcinoma. Oncologist, 15, 168-81.